Piet Ost, Radiation Oncologist Iridium Network Antwerp, shared a post on X about a recent abstract by him and colleagues, presented at 2025 ASCO Genitourinary Cancers Symposium:
“Does SBRT for oligorecurrent prostate cancer improve overall survival as compared to SOC? WOLVERINE reporting on STOMP, ORIOLE, EXTEND and ARTO.
Presented by Chad Tang at GU25.”
Authors: Chad Tang, Alexander Sherry, Hyunsoo Hwang, David Palma, Piet Ost et al.
